To enhance exosomes’ clinical applications, exosomal biomarkers should be compared and combined with other diagnostic methods, not only AFP, but also traditional HCC biomarkers like DCP and glypican-3, or histopathological biopsies and imaging tests, which have rarely been examined. This evidence concerns the gene AFP and hepatocellular carcinoma.